Table 3.

Summary of safety events during randomized retreatment period. Data are number of patients (%).

Safety EventsRetreatment with Placebo (n = 155)Retreatment with Rituximab (n = 320)
Adverse events119 (77)226 (71)
Serious adverse events11 (7)22 (7)
Infections59 (38)120 (38)
Serious infections3 (2)7 (2)
Adverse events leading to withdrawal7 (4)7 (2)
Deaths*1 (0.6)1 (0.3)
  • * One additional death in rituximab retreatment group after the Week 48 cutoff date.